secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113593
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE
--------------------------------------------------------------------------------

- Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.
- Closed PIPE with up to $102.9M gross proceeds (milestone-based); initial $24.5M at $1.82/share; led by Rosalind Advisors.
- Received EMA PRIME designation for iopofosine I 131 in WM after two or more prior treatments.
- Cash of $19.0M at Sep 30; net $22.2M from PIPE; believes funded into Q2 2024.
- Q3 R&D expense $7.3M (up from $5.4M YoY); G&A $2.1M (down from $2.4M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/0001104659-23-113593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/tm2329674d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer